Results 81 to 90 of about 51,283 (222)

Molecular modelling of S1 and S2 subunits of SARS coronavirus spike glycoprotein

Biochemical and Biophysical Research Communications, 2003
The S1 and S2 subunits of the spike glycoprotein of the coronavirus which is responsible for the severe acute respiratory syndrome (SARS) have been modelled, even though the corresponding amino acid sequences were not suitable for tertiary structure predictions with conventional homology and/or threading procedures.
Spiga, Ottavia, Bernini, A., Ciutti, A., Chiellini, S., Menciassi, N., Finetti, F., Causarano, V., Anselmi, F., Prischi, F., Niccolai, Neri   +9 more
openaire   +4 more sources

Molecular Aspects of Spike–ACE2 Interaction

Encyclopedia, 2022
A new betacoronavirus (CoV-2) is responsible for the pandemic of severe acute respiratory syndrome (SARS) that began in China at the end of 2019, today known as COronaVIrus Disease 2019 (COVID-19).
Luigi De Masi, Maria Antonia Argenio, Deborah Giordano, Angelo Facchiano   +3 more
doaj   +1 more source

Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus [PDF]

, 2014
Public health risks associated to infection by human coronaviruses remain considerable and vaccination is a key option for preventing the resurgence of severe acute respiratory syndrome coronavirus (SARS-CoV).
Bruzzone, R, Cheung, CY, Daëron, M, Jaume, MDA, Lee, HYH, LEUNG, HL, Li, PH, Peiris, JSM, Yip, MS   +8 more
core   +5 more sources

Disease–Drug–Drug Interaction of Imatinib in COVID‐19 ARDS: A Pooled Population Pharmacokinetic Analysis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.
ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said, Job R. Schippers, Leila Atmowihardjo, Yingxue Li, Mick S. van der Plas, Harm J. Bogaard, Lieuwe D. J. Bos, Ron A. A. Mathôt, Jurjan Aman, Eleonora L. Swart, Imke H. Bartelink   +10 more
wiley   +1 more source

Understanding Viral Transmission Behavior via Protein Intrinsic Disorder Prediction: Coronaviruses [PDF]

, 2012
Besides being a common threat to farm animals and poultry, coronavirus (CoV) was responsible for the human severe acute respiratory syndrome (SARS) epidemic in 2002-4. However, many aspects of CoV behavior, including modes of its transmission, are yet to
Dunker, A. Keith, Goh, Gerard Kian-Meng, Uversky, Vladmir N.   +2 more
core   +3 more sources

2019 Novel Coronavirus (COVID-19) Pandemic: Built Environment Considerations To Reduce Transmission. [PDF]

, 2020
With the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in coronavirus disease 2019 (COVID-19), corporate entities, federal, state, county, and city governments, universities, school districts, places of worship,
Coil, David A, Dietz, Leslie, Eisen, Jonathan A, Fretz, Mark, Horve, Patrick F, Van Den Wymelenberg, Kevin   +5 more
core   +2 more sources

Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq, Doni Dermawan, Samir Chtita   +2 more
wiley   +1 more source

Understanding the Molecular Actions of Spike Glycoprotein in SARS-CoV-2 and Issues of a Novel Therapeutic Strategy for the COVID-19 Vaccine

BioMedInformatics
In vaccine development, many use the spike protein (S protein), which has multiple “spike-like” structures protruding from the spherical structure of the coronavirus, as an antigen. However, there are concerns about its effectiveness and toxicity. When S
Yasunari Matsuzaka, Ryu Yashiro
doaj   +1 more source

Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins

Viruses, 2020
Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is responsible for the current global coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths.
Sai Priya Anand, Yaozong Chen, Jérémie Prévost, Romain Gasser, Guillaume Beaudoin-Bussières, Cameron F. Abrams, Marzena Pazgier, Andrés Finzi   +7 more
doaj   +1 more source

Potential antiviral peptides targeting the SARS-CoV-2 spike protein

BMC Pharmacology and Toxicology, 2022
Background The coronavirus disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection became an international pandemic and created a public health crisis.
Ibrahim Khater, Aaya Nassar
doaj   +1 more source